



## MEET THE SPEAKERS



**Dr Anna Olsson-Brown**, Consultant Medical Oncologist, University Hospitals Sussex NHS Foundation Trust

**When:** Saturday 18<sup>th</sup> April, 9.45am

**Session:** Late Effects and Survivorship

**Topic:** Service Development

Anna Olsson-Brown is a Professor of Clinical Cancer Trials and a Consultant in Medical Oncology. She specialises in the systemic treatment of skin cancers: immunotherapeutic toxicities, early phase/translational clinical trials, and NSS/CUP/acute oncology.

She is an academic consultant at UCC/CUH, an honorary academic at the University of Liverpool, an oncotoxicity consultant at University Hospitals Sussex and works within clinical leadership roles with both the Surrey and Sussex and West Midlands Cancer Alliances.

Anna has a background in clinical pharmacology and an interest in acute oncology and supportive care for cancer patients particularly with regards to toxicity of cancer therapies.

She was an MRC research fellow completing her PhD investigating the mechanisms of immunotherapy toxicity and has subsequently published extensively in the area (olsson-brown - Search Results - PubMed (nih.gov)).

Anna has established and led numerous acute and supportive oncology services including pan-tumour, pan-regional immunotherapy/oncotoxicity service supporting inpatients and outpatients with immunotherapy toxicities; also providing a clinical-research interface supporting a number of translational trials at both the Clatterbridge Cancer Centre, Liverpool and Sussex Cancer Centre, UHSx.



## MEET THE SPEAKERS

Anna sits on Cardio-oncology and Neuro-oncology toxicity MDTs at LHCH and UCLH respectively.

She has also established both an enhanced supportive care service and an oncofrailty service at UHSx. She has also spent 4 years as a clinical director prior to taking up her academic position.

She is the current Chair elect of the Association of Cancer Physicians/ UK Society of Medical Oncology (ACP/UKSMO). She is a founding member and current CEO of the National Immunotherapy Clinical Network (IOCN). She is the current Oncology representative of the Symposium Committee at the Royal College of Physicians of Edinburgh and sits on the UK SACT board. She is also the Toxicity Workstream Co-lead within the UK Acute Oncology Society and a trustee and board member of UKASCC.

**[>> Find out more – Visit the Conference Website](#)**